Plasma

For optimal results, draw immediately before IV (trough level).

1 mL plasma

Mean lanreotide levels +/- 2SD for patients on Somatuline Depot® injections for 4 or more months (steady-state). The following values represent trough levels of lanreotide measured immediately before a patient's next injection of Somatuline Depot.

Lanreotide administered as Somatuline® Depot:
480 mg/month: 20,000 pg/mL + 2,000 pg/mL
240 mg/month: 10,000 pg/mL + 2,000 pg/mL
120 mg/month: 5,000 pg/mL + 1,000 pg/mL
90 mg/month: 2,500 pg/mL + 500 pg/mL

Lanreotide (Somatuline Depot®, Tercica) is used for the control of symptoms associated with functional neuroendocrine tumors. Frequent measurement of the lanreotide levels may be useful in guiding therapy in patients with poorly controlled symptoms or those patients experiencing tumor growth. Lanreotide levels in blood need to be in a specific range to be effective. Measuring lanreotide immediately prior to the monthly injection will determine trough levels of the drug in your blood.

Lanreotide is measured by direct radioimmunoassay.

83519